Name (Synonyms) | Correlation | |
---|---|---|
drug2604 | Upadacitinib (ABT-494) Wiki | 1.00 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D014456 | Ulcer NIH | 0.41 |
D003092 | Colitis NIH | 0.41 |
D003093 | Colitis, Ulcerative NIH | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002583 | Colitis HPO | 0.41 |
HP:0100279 | Ulcerative colitis HPO | 0.41 |
There is one clinical trial.
High risk outpatient adult males with a confirmed SARS-CoV-2 infection will be included in the study. Patients will be randomized to receive Enzalutamide with standard of care (SOC) or SOC alone. Enzalutamide will be administered daily p.o. from Day 1 to Day 28 or until confirmed negativization of Nasopharyngeal swap (NPS) Polymerase chain reaction (PCR) (2 consecutive negative samples), whichever occurs first.
Description: efficacy of Enzalutamide in decreasing the nasopharyngeal swap SARS-CoV-2 viral load until negativization
Measure: Efficacy of Enzalutamide Time: 28 daysDescription: Efficacy of Enzalutamide in controlling disease progression of SARS-CoV-2 viral load
Measure: Disease progression Time: 28 daysDescription: Evaluation of Enzalutamide tolerability in terms of incidence and severity grade of side effects
Measure: Tollerability of Enzalutamide Time: 28 days